Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

Recruiting now

Conditions studied: Hepatitis C Virus (HCV)

In brief

The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.

Key facts

Study ID

NCT07419347

Run by

AbbVie

People needed

2000

Starts

2026-02-27

Expected to finish

2026-06-01

Last updated by the study team

2026-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P).
• Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.)
• Is concomitantly on one or more prescription medications or illicit drugs.

You may not qualify if…

• Treated with DAAs other than G/P.
• History of decompensated cirrhosis.
• Had Hepatitis-B virus (HBV) infection.
• Had hepatocellular carcinoma (HCC).

Where it is running

• Vancouver Infectious Diseases Centre /ID# 275313 — Vancouver, British Columbia, Canada (enrolling)
• St. Clair Medical Clinic /ID# 275334 — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.